Psycho-Babble Medication Thread 1122158

Shown: posts 1 to 2 of 2. This is the beginning of the thread.

FDA Approves zuranolone (Zurzuvae)

Posted by SLS on August 4, 2023, at 21:32:07

FDA Approves zuranolone First Oral Treatment for Postpartum Depression

https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-treatment-postpartum-depression

- Scott

Re: FDA Approves zuranolone (Zurzuvae)

Posted by SLS on August 8, 2023, at 9:35:52

In reply to FDA Approves zuranolone (Zurzuvae), posted by SLS on August 4, 2023, at 21:32:07

> FDA Approves zuranolone First Oral Treatment for Postpartum Depression
>
> https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-treatment-postpartum-depression
>
>
> - Scott

A reminder:

Zuronolone, adminstered orally, is a sister drug to brexanolone, a drug administered via I.V. to treat Postpartum Depression. As of today, zuranolone is FDA approved for treating postpartum depression. However, zuranolone has demonstrated a robust and rapidly-acting antidepressant response in clinical trials for both Major Depressive Disorder (MDD) and Bipolar Depression (BD).

Zuranolone has been observed to begin working within the first week. Also, it can be taken intermittently, although I don't see an advantage in doing this unless it is essential to glean a therapeutic effect.

The property that both zuranolone and brexanolone share, and presumed to be the mechanism of activation is that of a "positive allosteric modulator of GABA-A receptors" (Gamma-Aminobutyric Acid). In other words, zuranolone amplifies GABAergic neurotransmission. GABA generally acts as an inhibitor of excitatory pathways that are innervated by norepinephrine, dopamine, and glutamate. GABA is the main inhibitor to put the "brakes" on these pathways. Glycine fills this role as well.

-----------------------------------------------------------------

"Zuranolone by Sage Therapeutics for Treatment Resistant Depression: Likelihood of Approval"

https://www.pharmaceutical-technology.com/data-insights/zuranolone-sage-therapeutics-treatment-resistant-depression-likelihood-of-approval/

-----------------------------------------------------------------

- Scott

This is the end of the thread.

Show another thread

Psycho-Babble Medication | Extras | FAQ

Dr. Bob is Robert Hsiung, MD, [email protected]

Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.